Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis
NCT ID: NCT02468765
Last Updated: 2025-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
38 participants
OBSERVATIONAL
2015-04-24
2016-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Cognitive disorders, (particularly attention and dysexecutive disorders), appear in early stages of the disease's evolution, in cases of lightly or moderately disabled patients, with a recent evolution, with a "minor" form of the disease, even in Clinically Isolated Syndromes (CIS). Emotional disturbances are essentially linked to mood disorders of depression-type.
Last ten years, emotional processing in multiple sclerosis cases was investigated in various trials, especially regarding the recognition of facial and emotional expressions. These studies reported data, supporting an impairment of the perception of emotion, particularly those with negative valence.
The objective of this study is to investigate the link between recognition of facial and emotional expressions and depression in multiple sclerosis cases.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Emotions in Multiple Sclerosis
NCT04804787
Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis
NCT02708927
Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients
NCT02290587
Mood Disorders in Multiple Sclerosis Patients
NCT06652308
Identifying and Managing Psychological Distress in Multiple Sclerosis: The COMPASS-MS Study
NCT06222359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Moreover, although this deficit has been little studied, such a disorder could lead to difficulties in maintaining social interaction. These patients showed a deficit in learning and recognition of non-verbal social non-verbal social cues and emotional components, independently of the cognitive impairment but more marked in the case of a functional impairment and a longer duration of the disease.
Finally, there seems to be specific relationships between problems of of emotion and poor quality of life. Indeed, the levels of certain social and psychological aspects of quality of life in MS have been correlated with these emotion perception scores, highlighting the importance of considering these emotional emotional skills in assessing the impact of MS on the patient. on the patient. The correct analysis of EFEs is a complex mental process process, requiring the functional integrity of a number of cognitive domains (working memory, attention, visual-spatial perception and executive and executive functions). In view of the impact of depression on the analytical capacities of the EFEs, described in numerous studies, the high prevalence of and alexithymia in MS patients allows us to consider these two dimensions as to consider these two dimensions as factors that may influence their identification of EFEs.
Concerning alexithymia, one study has already observed its impact on the deficit of recognition of EFEs, but no study has investigated the link between depression and such a deficiency. However, the identification of a link between the recognition abilities of EFEs and these psycho-affective disturbances would allow the development of rehabilitative treatments aiming to limit the impact of the emotional fragility of patients in their daily life and, consequently, to improve their quality of life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Depressive MS patients
Neuropsychological and emotional evaluation with monitoring
Neuropsychological and emotional evaluation with monitoring
Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
Non depressive MS patients
Neuropsychological and emotional evaluation with monitoring
Neuropsychological and emotional evaluation with monitoring
Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
Control
Neuropsychological and emotional evaluation with monitoring
Neuropsychological and emotional evaluation with monitoring
Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neuropsychological and emotional evaluation with monitoring
Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant understanding and able to speak French
* Participant understanding the Participant Informed Sheet and who has signed the Informed Consent
* Participant with Health Insurance
MS Patients :
* Patient with relapsing remitting multiple sclerosis form
* Expanded Disability Status Scale (EDSS) \< 4
* Patient without motor disorders, cerebellar or significant upper limb somatosensory or visual disturbances
Control Participants :
* Participant without global cognitive deterioration
Exclusion Criteria
* Participant with other neurological pathologies, head trauma with loss of consciousness, psychiatric pathologies, serious general affections, alcoholism, perception disorders, dysarthria, disorders preventing oral communication and reading, under prescription of psychotropic drugs
* Mental or visual incapacity to take part in the study
* Participant with antecedents of drug or alcohol abuse
* Allergy to the components of the gel used during the EEG
* Patients with MRI contraindications : Pacemaker or neurostimulator or Implantable Cardioverter Defibrillator (ICD), Cochlear Implants, ocular or cerebral ferromagnetic foreign body close to the nerve structures, metal prostheses,
* Uncooperative or agitated patients,
* Claustrophobic patients,
* Ventricular peritoneal shunts and neurosurgical valves,
* Braces
* MS patient without MRI in the last 4 months
* Adults under guardianship, under judicial protection, persons deprived of liberty,
* Pregnant or breast feeding women,
* MS patient with another MS form than Relapsing-Remitting,
* MS patient who encountered a relapse in the last 6 weeks,
* MS patient treated with corticoids in the last month.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lille Catholic University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrick Hautecoeur, MD
Role: PRINCIPAL_INVESTIGATOR
Groupment des Hôpitaux de l'Institut Catholique de Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Saint Vincent de Paul (GHICL)
Lille, Hauts-de-France, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC-P0040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.